Etanercept in dermatological practice - Authors' own experience in the treatment of psoriasis vulgaris and psoriatic arthritis

Postepy Dermatologii i Alergologii

Volumn 28, Issue 6, 2011, Pages 435-441

  Adamski, Zygmunt ^a,b   Dudziak, Małgorzata ^a   Zakrzewska, Katarzyna ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Provincial Hospital   (Poland)

Author keywords

Etanercept; Psoriasis area and severity index; Psoriatic arthritis; Tumour necrosis factor

Indexed keywords

ETANERCEPT;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL PRACTICE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE REACTION; MALE; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 84855168698     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-50. (Pubitemid 351509656)
2. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overwiev and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58: 851-64. (Pubitemid 351509657)
3. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-42.
4. Gefland JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis; results from a population-based study. Arch Dermatol 2007; 143: 1493-9. (Pubitemid 350277763)
5. Taylor WJ. Epidemiology of psoriatic arthritis. Curr Opin Rheumatol 2002; 14: 98-103.
6. Gladman DD. Psoriatic arthritis. Dermatol Ther 2004; 17: 350-63.
7. Scarpa R, Oriente P, Pucino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984; 23: 246-50. (Pubitemid 14015860)
8. Espinoza LR, Cuellar ML, Silveira LH. Psoriatic arthritis. Curr Opin Rheumatol 1992; 4: 470-8.
9. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20. (Pubitemid 34204344)
10. Brockbank J, Gladman D. Diagnosis and managment of psoriatic arthritis. Drugs 2002; 62: 2447-57.
11. Wolska H. Łuszczyca paznokci. Przegl Dermatol 2010; 97: 243-52.
12. Gladman DD. The natural history of psoriatic arthritis. In: Psoriatic arthritis in Baillière's Clinical Rheumatology. International Practice and Research. Wright V, Helliwell PS (eds.). London: Baillière Tindall, 1994; 379-94.
13. Parstsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-23. (Pubitemid 27153418)
14. Ettehadi P, Greaves MV, Wallach D, Aderka D, Camp RD. Elevated tumor necrosis factor-alpha (TNFalpha) biological activity in psoriatic skin lesions. Clinic Exp Immunol 1994; 96: 146-51. (Pubitemid 24213812)
15. Sibilla J. Psoriasis: skin and joints, same fight? J Eur Acad Dermatol Vener 2006; 20: 56-72.
16. Amgen Inc and Wyeth Pharmaceuticals Enbrel R (etanercept) prescribing information. Amgen Inc and Wyeth Pharmaceuticals, 2011.
17. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32. (Pubitemid 37523083)
18. Leonardi CL, Powers JL, Matheson RT, et al.; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22. (Pubitemid 37448924)
19. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35. (Pubitemid 43038667)
20. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56: 598-603. (Pubitemid 46400183)
21. Papp KA, Tyring S, Lahfa M, et al.; Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-12. (Pubitemid 40933433)
22. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90. (Pubitemid 30487495)
23. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72. (Pubitemid 38924405)
24. Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatol Treat 2006; 17: 343-52. (Pubitemid 46895587)
25. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340: c147.
26. Mazzotta A, Esposito M, Schipani C, Chimenti S. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study. J Dermatol Treat 2009; 20: 354-8.
27. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241-51.
28. Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 2010; 63: 762-8.
29. Tyc-Zdrojewska E, Kaszuba A, Michalak I, Kaszuba A. Preparaty biologiczne w terapii łuszczycy - doświadczenia własne. Forum Medycyny Rodzinnej 2009; 6: 468-79.
30. Coelho JD, Diamantino F, Lestre S, Ferreira AM. Treatment of severe nail psoriasis with etanercept. Indian J Dermatol Venereol Leprol 2011; 77: 72-4.
31. Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, et al. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol 2011; 25: 579-86.
32. Girolomoni G, Gottlieb A. Focus on psoriatic arthritis and comorbidities. Expert Rev Dermatol 2008; 3 (4 Suppl 1): 35-6.